Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Neural Plasticity|June 2, 2018
Guiding Lights in Genome Editing for Inherited Retinal Disorders: Implications for Gene and Cell TherapyCarla Sanjurjo-Soriano, Vasiliki Kalatzis
Methods in Molecular Biology (Clifton, N.J.)|March 23, 2021
CRISPR/Cas9-Mediated Genome Editing to Generate Clonal iPSC LinesCarla Sanjurjo-Soriano, Nejla Erkilic, Daria Mamaeva, et al.
International Journal of Molecular Sciences|April 3, 2021
Allele-Specific Knockout by CRISPR/Cas to Treat Autosomal Dominant Retinitis Pigmentosa Caused by the G56R Mutation in NR2E3Michalitsa Diakatou, Gregor Dubois, Nejla Erkilic, et al.
Stem Cell Research|November 24, 2018
Generation of a human iPSC line, INMi002-A, carrying the most prevalent USH2A variant associated with Usher syndrome type 2Carla Sanjurjo-Soriano, Nejla Erkilic, Gaël Manes, et al.
Stem Cell Research|March 6, 2022
Generation of a human iPSC line, INMi005-A, from a patient with non-syndromic USH2A-associated retinitis pigmentosaCarla Sanjurjo-Soriano, Nejla Erkilic, Christel Vache, et al.
Stem Cell Research|November 20, 2018
Generation of an iPSC line, INMi001-A, carrying the two most common USH2A mutations from a compound heterozygote with non-syndromic retinitis pigmentosaCarla Sanjurjo-Soriano, Nejla Erkilic, Gaël Manes, et al.
Stem Cell Research|June 28, 2019
Generation of a human iPSC line, INMi004-A, with a point mutation in CRX associated with autosomal dominant Leber congenital amaurosisNejla Erkilic, Carla Sanjurjo-Soriano, Gaël Manes, et al.
Stem Cell Research|June 17, 2019
Generation of a human iPSC line, INMi003-A, with a missense mutation in CRX associated with autosomal dominant cone-rod dystrophyNejla Erkilic, Carla Sanjurjo-Soriano, Michalitsa Diakatou, et al.
Molecular Therapy. Methods & Clinical Development|January 8, 2020
Genome Editing in Patient iPSCs Corrects the Most Prevalent USH2A Mutations and Reveals Intriguing Mutant mRNA Expression ProfilesCarla Sanjurjo-Soriano, Nejla Erkilic, David Baux, et al.
Molecular Therapy. Methods & Clinical Development|December 11, 2025
Erratum: Genome Editing in Patient iPSCs Corrects the Most Prevalent USH2A Mutations and Reveals Intriguing Mutant mRNA Expression ProfilesCarla Sanjurjo-Soriano, Nejla Erkilic, David Baux, et al.
Pageof 2